Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025The LaryngoscopeOpen Access

GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?

View Full Paper
Ask AI
Bookmark
Share

Authors

AZAlina ZgardauRCRyan Chin Taw CheongKPKenny P. Pang

Discussion

Loading...

Member takes

Overview

Observational review reveals GLP-1 receptor agonists reduce apnea-hypopnea index in OSA patients, suggesting a novel treatment avenue.

Key Points

  • GLP-1 receptor agonists like tirzepatide significantly reduce apnea-hypopnea index, while improving weight and blood pressure.
  • In trials, tirzepatide led to a significant AHI reduction of 25.3 events/h compared to placebo and a 19.6% reduction in weight.
  • Systematic review supports the role of GLP-1 receptor agonists in OSA management, emphasizing improved patient outcomes alongside existing therapies.
  • Using GLP-1 receptor agonists may optimize surgical outcomes for OSA by reducing BMI and severity of the condition.

Cite This Study

Zgardau et al. (2025) studied this question.

synapsesocial.com/papers/68c1bb7854b1d3bfb60edd26https://doi.org/10.1002/lary.70022
View Full Paper
Ask AI
Bookmark
Share